BioCentury | Feb 27, 2020
Product Development

Feb. 26 Quick Takes: Takeda acquires PvP for celiac therapy; plus Lilly, Esperion, Supernus, Moderna, Taiho-Arcus, Twist-Sophia

...an undisclosed upfront payment plus up to $330 million in milestones. TAK-062 (formerly Kuma062), a gluten-degrading...
BioCentury | Oct 23, 2019
Company News

Celiac data persuade Takeda to commit to Cour’s tolerance-inducing therapy

...Phase IIa trial for the disease, an autoimmune disorder in which ingestion of the allergen gluten...
...disease at baseline, were administered IV TAK-101 at days 1 and 8, and underwent daily gluten...
...plans to start a dose-ranging study of the inflammatory monocyte-targeted nanoparticles delivering gliadin proteins -- gluten...
BioCentury | Aug 15, 2019
Product Development

Adaptive is surfing a wave of enthusiasm in disease detection, betting on the immune system

...its blood test will offer a less invasive alternative to current diagnostic methods, which include gluten...
BioCentury | Jul 26, 2019
Product Development

Institute for Protein Design's de novo revolution

...therapeutics spinouts. Launched in 2016 with a Takeda build-to-buy deal, PvP Biologics developed its engineered gluten-degrading...
...enzyme KumaMax by using Rosetta to make a naturally occurring bacterial enzyme highly specific for gluten...
...Takeda has an exclusive option to acquire PvP upon receipt of Phase I data (see "Gluten-Free...
BioCentury | Feb 27, 2019
Finance

Calypso finds its rhythm

...in November to co-develop AMG 714 (PRV-015), a Phase IIb mAb against IL-15 to treat gluten...
BioCentury | Jan 26, 2019
Product Development

Raising the BD bar

...candidate, Nexvax2, is an epitope-specific immunotherapy consisting of three immunodominant peptides designed to protect against gluten...
...of a negative response -- was measured as an interferon γ (IFNγ) reaction upon a gluten...
BioCentury | Nov 29, 2017
Emerging Company Profile

Gluten-free gut

...PvP Biologics Inc. is developing an oral enzyme therapy for celiac disease to break down gluten...
...immune system, where other competitors act. Patients with celiac disease produce antibodies that attack dietary gluten...
...it passes through the intestine, causing severe intestinal damage and malnutrition. Even with a strict gluten-free...
BioCentury | Nov 17, 2017
Finance

Stepwise progress

...intradermal vaccine consisting of three immunodominant peptides designed to reprogram CD4+ T cells to induce gluten...
...trials in 2012 evaluating multiple fixed-dose regimens of Nexvax2, but patients experienced symptoms related to gluten...
...said Williams. The Phase IIb trial, which will evaluate Nexvax2 as an adjunct to a gluten-free...
BioCentury | Nov 17, 2017
Financial News

Venture roundup: ImmusanT, Locus

...The candidate is an epitope-specific immunotherapy consisting of three immunodominant peptides designed to protect against gluten...
BioCentury | Nov 15, 2017
Financial News

Venture Roundup: ImmusanT, Locus

...The candidate is an epitope-specific immunotherapy consisting of three immunodominant peptides designed to protect against gluten...
Items per page:
1 - 10 of 64